Literature DB >> 24406506

Immune cell subset counts associated with graft-versus-host disease.

Peter J Podgorny1, Yiping Liu2, Poonam Dharmani-Khan2, Laura M Pratt2, Kareem Jamani2, Joanne Luider2, Iwona Auer-Grzesiak2, Adnan Mansoor2, Tyler S Williamson2, Alejandra Ugarte-Torres2, Mette Hoegh-Petersen2, Douglas A Stewart2, Andrew Daly2, Faisal M Khan2, James A Russell2, Jan Storek2.   

Abstract

Graft-versus-host disease (GVHD) is a major transplantation complication. The purpose of this study was to measure immune cell subsets by flow cytometry early after transplantation (before median day of GVHD onset) to identify subsets that may play a role in GVHD pathogenesis. We also measured the subsets later after transplantation to determine which subsets may be influenced by GVHD or its treatment. We studied 219 patients. We found that acute GVHD (aGVHD) was preceded by high counts of CD4 T cells and CD8 T cells. It was followed by low counts of total and naive B cells, total and cytolytic NK cells, and myeloid and plasmacytoid dendritic cells. Chronic GVHD (cGVHD) was preceded by low counts of memory B cells. In conclusion, both CD4 and CD8 T cells appear to play a role in the pathogenesis of aGVHD. Generation of B cells, NK cells, and dendritic cells may be hampered by aGVHD and/or its treatment. Memory B cells may inhibit the development of cGVHD.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B lymphocytes; Dendritic cells; Graft-versus-host disease; Hematopoietic cell transplantation; NK cells; T lymphocytes

Mesh:

Year:  2014        PMID: 24406506     DOI: 10.1016/j.bbmt.2014.01.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  22 in total

1.  Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation.

Authors:  Raphael Itzykson; Marie Robin; Helene Moins-Teisserenc; Marc Delord; Marc Busson; Aliénor Xhaard; Flore Sicre de Fontebrune; Régis Peffault de Latour; Antoine Toubert; Gérard Socié
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

2.  Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.

Authors:  Nannan Pang; Xianlin Duan; Ming Jiang; Jianhua Qu; Hailong Yuan; Jianli Xu; Haizhou Cao; Gang Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

Authors:  Ryan H Moy; Austin P Huffman; Lee P Richman; Lisa Crisalli; Ximi K Wang; James A Hoxie; Rosemarie Mick; Stephen G Emerson; Yi Zhang; Robert H Vonderheide; David L Porter; Ran Reshef
Journal:  Blood       Date:  2017-01-05       Impact factor: 22.113

4.  Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD.

Authors:  Eleonora Latis; David Michonneau; Claire Leloup; Hugo Varet; Régis Peffault de Latour; Elisabetta Bianchi; Gérard Socié; Lars Rogge
Journal:  Blood Adv       Date:  2020-08-25

5.  Conformal Nanoencapsulation of Allogeneic T Cells Mitigates Graft-versus-Host Disease and Retains Graft-versus-Leukemia Activity.

Authors:  Shuting Zhao; Lingling Zhang; Jianfeng Han; Jianhong Chu; Hai Wang; Xilin Chen; Youwei Wang; Norm Tun; Lanchun Lu; Xue-Feng Bai; Martha Yearsley; Steven Devine; Xiaoming He; Jianhua Yu
Journal:  ACS Nano       Date:  2016-05-31       Impact factor: 15.881

6.  Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

Authors:  Ana C Alho; Haesook T Kim; Marie J Chammas; Carol G Reynolds; Tiago R Matos; Edouard Forcade; Jennifer Whangbo; Sarah Nikiforow; Corey S Cutler; John Koreth; Vincent T Ho; Philippe Armand; Joseph H Antin; Edwin P Alyea; Joao F Lacerda; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

7.  A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.

Authors:  Emily J Pomeroy; John T Hunzeker; Mitchell G Kluesner; Walker S Lahr; Branden A Smeester; Margaret R Crosby; Cara-Lin Lonetree; Kenta Yamamoto; Laura Bendzick; Jeffrey S Miller; Melissa A Geller; Bruce Walcheck; Martin Felices; Beau R Webber; Timothy K Starr; Branden S Moriarity
Journal:  Mol Ther       Date:  2019-10-15       Impact factor: 11.454

8.  Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation.

Authors:  Evelyn Ullrich; Emilia Salzmann-Manrique; Shahrzad Bakhtiar; Melanie Bremm; Stephanie Gerstner; Eva Herrmann; Peter Bader; Petra Hoffmann; Ernst Holler; Matthias Edinger; Daniel Wolff
Journal:  Front Immunol       Date:  2016-12-22       Impact factor: 7.561

9.  Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML.

Authors:  Ulla Impola; Antti Larjo; Urpu Salmenniemi; Mervi Putkonen; Maija Itälä-Remes; Jukka Partanen
Journal:  Front Immunol       Date:  2016-11-21       Impact factor: 7.561

10.  Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.

Authors:  Rehan Mujeeb Faridi; Taylor J Kemp; Poonam Dharmani-Khan; Victor Lewis; Gaurav Tripathi; Raja Rajalingam; Andrew Daly; Noureddine Berka; Jan Storek; Faisal Masood Khan
Journal:  PLoS One       Date:  2016-06-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.